Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 4, 2016, Pages 787-795

  Tamura, Kenji ^a   Hashimoto, Jun ^a   Tanabe, Yuko ^a   Kodaira, Makoto ^a   Yonemori, Kan ^a   Seto, Takashi ^b   Hirai, Fumihiko ^b   Arita, Shuji ^b   Toyokawa, Gouji ^b   Chen, Lan ^c   Yamamoto, Hiroshi ^c   Kawata, Toshio ^c   Lindemann, Justin ^c   Esaki, Taito ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Akt inhibitor; Akt1 (E17K) mutation; AZD5363; Safety; Solid tumor

Indexed keywords

4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; CREATININE; HEMOGLOBIN A1C; 4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; AKT1 PROTEIN, HUMAN; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL BLEEDING; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOXIA; JAPANESE (PEOPLE); LEUKOCYTE COUNT; LIVER CANCER; LUNG CANCER; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; ORAL MUCOSITIS; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PLEURA CANCER; PRIORITY JOURNAL; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERUS CANCER; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; MUTATION; NEOPLASMS;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES;

EID: 84959338095     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-2987-9     Document Type: Article

References (15)

1. Lindsley CW (2010) The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 10:458-477
2. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29-86
3. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, McKenna WG (2003) Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56:846-853
4. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205-3212
5. Khan KH, Yap TA, Yan L, Cunningham D (2013) Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 32:253-265
6. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, Ricketts SA, Cross D, Cosulich S, Chresta CC, Page K, Yates J, Lane C, Watson R, Luke R, Ogilvie D, Pass M (2012) Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11:873-887
7. Banerji U, Dean EJ, Perez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Davies B, Elvin P, Lawrence P, Yates JW, Ambrose H, Rugman P, Foxley A, Salim S, Casson E, Lindemann JP, Schellens JH (2015) A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT ihibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. 51st Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 29 May - 2 June: abst 2500
8. AstraZeneca (2015) Global policy: bioethics. Available at: http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies
9. Coban E, Ozdogan M, Timuragaoglu A (2004) Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol 112:126-128
10. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S, Rosen N (2014) Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 4:334-347
11. Dean EJ, Banerji U, Schellens JH, Krebs M, Jimenez B, van der Noll R, Foxley A, Yates JW, Taylor N, Evans S, Guy T, Casson E, Rugman P, Salim S, Lindemann JP, Lawrence P (2015) Results of OAK: a phase 1, open-label, multicentre study to compare two dosage forms of AZD5363 and to explore the effect of food on the pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in patients with advanced solid malignancies. 51st Annual meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 29 May - 2 June: abst 2577
12. Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, Brown KK, Kumar R (2009) Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 15:217-225
13. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF (2006) Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 17:2236-2244
14. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688-4695
15. Davies B, Guan N, Logie A, Crafter C, Hanson L, Jacobs V, James N, Dudley P, Jacques K, Ladd B, D'Cruz CM, Zinda M, Lindemann J, Kodaira M, Tamura K, Jenkins EL (2015) Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors. Mol Cancer Ther 14:2441-2451